Australia Introduces ‘Appendix M’ Criteria To Facilitate Innovative Switches
Executive Summary
Australia's Therapeutic Goods Administration has introduced a set of criteria introducing additional controls for medicines rescheduled from ‘Schedule 4’ (prescription-only) to ‘Schedule 3’ (non-prescription, pharmacist-only) status, intended to facilitate more innovative prescription-to-OTC switches in the future.
You may also be interested in...
Triptan Switches Offer Hope For Australia’s OTC Market
Switch expert Natalie Gauld says recent triptan switch recommendations signal a turnaround for Australia's OTC market.
Norway Model Offers Key To Unlock More Complex Switches
Norway's move to encourage more innovative Rx-to-OTC switches has begun to bear fruit with the recent reclassification of Pfizer's Viagra. The country's decision to introduce a new non-prescription drug category to promote switching can be used as a model for securing a new wave of more complex switches elsewhere around the world.
Norway Model Offers Key To Unlock More Complex Switches
Norway's move to encourage more innovative Rx-to-OTC switches has begun to bear fruit with the recent reclassification of Pfizer's Viagra. The country's decision to introduce a new non-prescription drug category to promote switching can be used as a model for securing a new wave of more complex switches elsewhere around the world.